Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
RDN
0.007
75%
HMD
0.012
-36.8%
XAM
0.079
54.9%
ERA
0.002
-33.3%
NSX
0.033
50%
EIQ
0.24
-25%
ROG
0.005
25%
ICR
0.006
-25%
LDR
0.16
23.1%
MMR
0.003
-25%
MGA
0.061
22%
AZL
0.007
-22.2%
FRS
0.075
21%
ATX
0.051
-21.5%
OD6
0.03
20%
C1X
0.055
-21.4%
AM5
0.013
18.2%
TEM
0.004
-20%
BLU
0.007
16.7%
HCT
0.045
-19.6%
CLA
0.007
16.7%
ANR
0.005
-16.7%
CTQ
0.014
16.7%
AQX
0.005
-16.7%
HOR
0.021
16.7%
EMU
0.02
-16.7%
M24
0.014
16.7%
MEM
0.005
-16.7%
SPX
0.007
16.7%
RC1
0.005
-16.7%
OFX
1.315
16.4%
T92
0.025
-16.7%
OSX
0.015
15.4%
LTR
0.68
-16.6%
EXR
0.031
14.8%
ORD
0.39
-16.1%
EOS
1.48
14.7%
APX
1.23
-15.8%
AHF
0.047
14.6%
IVX
0.081
-14.7%
